Biktarvy
Largest product: $3.77 billion of sales in Q2 2026, up 7% year over year.
The numbers
What it is
Biktarvy is a once-daily single-tablet HIV treatment and Gilead's largest product. Its 2025 sales were $14.3 billion, up 7%, and its growth is now in single digits as the franchise matures.
Why it matters to the stock. Biktarvy sets the pace for the whole company. The ISLEND-1 study tests a once-weekly switch from Biktarvy, so this franchise also faces its own successor.
News
FDA approves Bixlenvo, Gilead's once-daily bictegravir and lenacapavir HIV pill
The FDA approved Bixlenvo (bictegravir 75 mg and lenacapavir 50 mg), a once-daily single-tablet HIV regimen for adults who are virologically suppressed and can replace their current regimen.
Gilead Q2 2026 revenue rises 10% to $7.8 billion; GAAP loss on acquired R&D charges
Gilead reported second-quarter 2026 total revenue of $7,803 million, up 10% from a year earlier, led by HIV medicines, Trodelvy and Livdelzi.
Gilead and Merck report Week 48 data for once-weekly oral HIV pill islatravir/lenacapavir
Gilead and Merck reported Week 48 Phase 3 results for once-weekly islatravir and lenacapavir, meeting the primary endpoint in both ISLEND trials.
Gilead and Merck report positive Phase 3 ISLEND-1 and ISLEND-2 results for once-weekly HIV pill
Gilead and Merck said both Phase 3 ISLEND trials of once-weekly oral islatravir plus lenacapavir met their Week 48 primary endpoint.
Gilead Q1 2026 beats: product sales ex-Veklury up 8%, product guidance raised, EPS guidance cut to a loss
Gilead's first-quarter revenue rose 4% to $6.96 billion, and product sales excluding Veklury grew 8% to $6.8 billion.
FDA grants priority review to Gilead's once-daily bictegravir plus lenacapavir HIV pill
The FDA accepted Gilead's new drug application for a once-daily single tablet of bictegravir 75 mg and lenacapavir 50 mg and granted priority review.
Gilead reports 2025 results and guides 2026 product sales to $29.6-30.0 billion
Gilead reported fourth-quarter and full-year 2025 results and set 2026 guidance.